Recruiting
Phase 3

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Sponsor:

Arog Pharmaceuticals, Inc.

Code:

NCT03258931

Conditions

Newly Diagnosed FLT3 Mutated AML

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Crenolanib

Midostaurin

Cytarabine

Duanorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information